Is Compounded Semaglutide Still Legal in 2026? Current Status

By the Peptide Dossier Editorial Team · Evidence checked October 21, 2026.

This guide organizes records relevant to compounded semaglutide: federal conditions, shortage decisions, agency letters, private disputes, and court opinions. Use the separate sections to prepare questions for your prescriber and pharmacist.

The Current Legal Status: Federal Conditions After the Shortage

Compounded semaglutide must fit an applicable legal pathway; a prescription alone is not enough. The FDA's comparison of the compounding provisions explains that the federal exemptions depend on meeting all applicable conditions. They are not approval of a compounded product.

Section 503A generally involves an identified-patient prescription, limited anticipatory preparation, and restrictions on copies of commercially available drugs. A prescriber-determined significant difference can matter; adding B12 alone does not establish it. Section 503B permits a separate outsourcing-facility pathway without individual prescriptions, with distinct bulk-substance and other conditions, including current good manufacturing practice. Read the 503A statute and 503B statute together with current FDA guidance.

That distinction matters for patients using compounded semaglutide. Ask separately who prescribes, who compounds, and who dispenses the product. A platform's branding may not identify the actual compounder; the FDA specifically cautions against misleading branding and facility-approval claims in its telehealth marketing guidance.

Shortage List Removal: The Turning Point in February 2025

The FDA's February 21, 2025 order resolved the injectable semaglutide shortage under the terms of that order. The chronology is worth keeping precise: the order records Wegovy on the shortage list beginning in March 2022 and Ozempic beginning in August 2022, rather than 2021. A national shortage determination is not a promise that every U.S. pharmacy has stock, and local fulfillment can still differ.

The February 21 order originally set April 22, 2025 for 503A and May 22 for 503B. On March 10, FDA extended each period to its original end date or the injunction decision, whichever was later. Its April 28 update confirmed 503A discretion had ended after the April 24 injunction denial; 503B discretion continued through May 22. Those temporary periods are not ongoing permissions to copy approved products.

A local backorder or high price does not itself put a drug back on the federal shortage list. Ask which specific pathway and current official record the pharmacy is relying on, rather than accepting "shortage" as a complete explanation.

FDA Regulatory Enforcement and Where It's Heading

FDA warning letters are public agency communications about specific conduct. The FDA's telehealth-compounding page points readers to a searchable warning-letter database and describes concerns such as implying that a compounded product is the same as an approved drug, using platform branding in a way that obscures the compounder, or making unsupported facility-approval claims.

On March 3, 2026, the FDA announced a group of 30 letters concerning false or misleading website claims about compounded GLP-1s. The bulletin described that group as a second group since a September campaign; it should not be turned into an unsupported cumulative total, a universal shutdown count, or a prediction of prosecution. Enforcement records are case-specific.

A September 9, 2025 letter to Hims & Hers dba Hers alleged misleading promotion of compounded semaglutide and described possible remedies if the concerns were not corrected. It is an agency allegation addressed to a named recipient, not a court finding, a current status report about every recipient, or proof that a company shut down. Read the named letter and response history before drawing a broader conclusion.

Novo Nordisk’s Patent Suit and March 2026 Agreement

This guide keeps private disputes separate from agency conditions. The following records show what Novo announced, rather than an independent ruling on infringement or a blanket conclusion about compounding.

In a February 9, 2026 company statement, Novo Nordisk announced a patent suit against Hims over patent 8,129,343. That statement reports Novo's allegations; it is not an independent finding that infringement occurred, that all compounded semaglutide products are covered, or that a compounder has universal immunity.

In a March 9, 2026 company announcement, Novo said an agreement with Hims included branded access, ending advertising for compounded GLP-1 offerings, and clinically appropriate professional-led transitions. It also said the patent suit would be dismissed while reserving refiling. Those are dated private-party announcements, not a substitute for the court docket or a claim that every private dispute has the same outcome.

Patient-Specific vs. Mass-Market Compounding Distinction

Patient-specific compounding under 503A is organized around an identified patient and a valid prescription, with limited anticipatory preparation allowed under the statute. The significant-difference question is tied to the prescriber and the documented patient need. Marketing language, personalization, or an added ingredient does not automatically answer that question.

For section 503B, bulk substances generally require a clinical-need-list basis or a drug shortage at compounding, distribution, and dispensing, alongside other conditions. "Bulk" refers to the ingredient, not batch size. Restrictions on essentially copying an approved drug remain separate. Read FDA’s bulk-substance framework, its published list and subsequent notices; registration alone does not settle eligibility.

Ask who prescribes, compounds, and dispenses, and what pathway each believes applies. Have the prescriber or pharmacist explain the prescription basis and exact formulation; do not use a checkout flow or the phrase "patient-specific" as the whole answer.

Court Challenges and the Shortage Decision

In the Fifth Circuit opinion filed August 27 and revised September 1, 2026, the court affirmed the district-court judgment in the semaglutide shortage-delisting challenge. It concluded that any notice-and-comment error was harmless and the delisting was not arbitrary or capricious. The opinion is not designated for publication.

That decision addresses the FDA's shortage determination, not every compounded preparation or private patent dispute. It is a dated appellate ruling, not a claim that all related litigation has ended. Anyone relying on its procedural status should check for subsequent court orders.

For a current legal question, ask which official agency notice or court order applies. Compare dated proposals, final actions, and court decisions separately, including their dates and scope; do not use a policy campaign or platform summary as the only record.

Alternative GLP-1 Options and Medication Choices

If compounded semaglutide is unavailable or no longer fits the prescriber's assessment, approved products are options for a form- and indication-specific discussion. The Ozempic prescribing information identifies type 2 diabetes use. The Wegovy label covers specified weight-management indications, and the Zepbound label covers specified weight-management and obstructive-sleep-apnea indications. Those products do not all have the same indications, coverage, cost, or dosing.

Do not assume an approved product is automatically covered, cheaper, or interchangeable with a compounded product. Do not carry a compounded syringe's units into a different concentration, device, or label. A prescriber must decide whether an approved product fits the indication and patient history, and the product label controls its own dosing and warnings.

AOD-9604 and combinations involving Ipamorelin are research topics, not established GLP-1 replacements. Two short trials of long-acting CJC-1295 in healthy adults reported higher growth hormone and IGF-I; they did not establish weight-loss efficacy or test an ipamorelin combination. The FDA's compound-specific safety summaries describe limited data for AOD-9604 and CJC-1295 and concerns about ipamorelin. Evidence about one compound, formulation, or route should not be treated as evidence about another.

Practical Guidance for Patients Currently Using Compounded Semaglutide

FDA’s concerns about unapproved GLP-1 drugs explain why product-specific questions matter. If you use compounded semaglutide, ask the prescribing clinician and dispensing pharmacist to review your exact product and options. For a non-urgent decision, discuss continuity rather than using a blanket instruction to stop or continue.

Before any change, confirm the dispensing pharmacy, formulation, milligram dose, milligrams per milliliter, device, storage instructions, and beyond-use date. The FDA's dosing-error alert describes problems involving concentration, milligrams per milliliter, units, and devices. Units from one concentration cannot safely be carried over to another product without professional confirmation.

For a serious allergic reaction or severe persistent abdominal pain, seek immediate medical help and do not take another dose until urgently advised by a clinician. The Ozempic medication guide identifies these as reasons to stop treatment and obtain help, not wait for a routine switching appointment. That branded guide does not verify a compounded product's contents.

FDA flags improper refrigeration during shipping as a quality concern. If a product’s source changes, ask the compounder or prescriber to verify its label, storage instructions, concentration, device, and beyond-use information. Do not assume the previous product’s instructions carry over.

The Cost and Access Dilemma

Cost is a real access issue, but there is no universal price comparison that answers the legal or clinical question. Compare the actual recurring total: medication, consultation, shipping, eligibility requirements, supplies, and expected follow-up. Ask the insurer and prescriber what is covered and what alternatives are available. Do not treat a lower advertised price as proof of equivalent product, lawful preparation, or guaranteed savings.

Ask for the renewal price as well as any introductory offer, and whether a change in dose affects the total. Have the insurer or provider confirm coverage for the actual product and indication. Keep price, clinical suitability, and the pharmacy's legal basis as separate questions.

Future Outlook: What to Expect in 2026 and Beyond

The FDA announced a proposal on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk list. The proposal was published on May 1. A June 26 Federal Register notice extended the comment deadline to July 30, 2026, at 11:59 p.m. Eastern. A proposal and a comment extension are not a final determination.

Check subsequent FDA notices and court orders before relying on that proposal's current status; the dates above describe the proposal and comment process, not a final disposition. Ask the pharmacy or prescriber to identify the product-specific federal and state requirements they believe apply.

The durable patient step is a current, documented plan: know who prescribed and dispensed the product, confirm the concentration and beyond-use date, and discuss approved or other lawful options before access becomes urgent. Legal eligibility, product quality, approval, and patient benefit remain separate questions even as agency actions and private disputes about compounded semaglutide develop.